Featured Research

from universities, journals, and other organizations

The Protein CCKR2: A Potential Drug Target For Colorectal Cancer?

Date:
August 3, 2009
Source:
Journal of Clinical Investigation
Summary:
Colorectal cancer is the second most common cause of death from cancer in the United States. Research in mice has now linked the protein CCKR2 with a colonic change associated with colorectal cancer, leading the authors to suggest that CCKR2 may be a viable target for the development of drugs to treat or prevent colorectal cancer.

Colorectal cancer, the second most common cause of death from cancer in the United States, is associated with an abnormally high rate of increase in the number of cells lining the colon (colonic hyperproliferation). In mice, overexpression of the human protein progastrin has been shown to cause colonic hyperproliferation and promote colorectal cancer, but the molecular mechanisms underlying this have remained undetermined.

In a new study, Timothy Wang and colleagues, at Columbia University Medical Center, New York, have revealed a key link between the protein CCKR2 and progastrin-related colonic hyperproliferation. Initial analysis indicated that the Cck2r gene was upregulated in mice that overexpressed human progastrin.

Deletion of this gene in mice that overexpressed human progastrin abolished the colonic hyperproliferation induced by the high levels of human progastrin and markedly diminished the extent of experimentally induced colorectal cancer. As previously published data indicate that levels of progastrin might be elevated in individuals with colorectal cancer, the authors conclude that their study suggests that CCKR2 may be a viable target for the development of drugs to treat or prevent colorectal cancer.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jin et al. Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI38918

Cite This Page:

Journal of Clinical Investigation. "The Protein CCKR2: A Potential Drug Target For Colorectal Cancer?." ScienceDaily. ScienceDaily, 3 August 2009. <www.sciencedaily.com/releases/2009/08/090803173110.htm>.
Journal of Clinical Investigation. (2009, August 3). The Protein CCKR2: A Potential Drug Target For Colorectal Cancer?. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/08/090803173110.htm
Journal of Clinical Investigation. "The Protein CCKR2: A Potential Drug Target For Colorectal Cancer?." ScienceDaily. www.sciencedaily.com/releases/2009/08/090803173110.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins